Cantargia AB (publ) (CANTA.ST) Stock Analysis & Winston Score

Cantargia AB is a Swedish biotech company that develops experimental drugs to treat cancer. Its main focus is on blocking a protein called IL1RAP, which plays a role in how certain tumors grow and spread. The company's lead drug candidate, nadunolimab, is being tested in clinical trials for cancers including pancreatic cancer and lung cancer. Cantargia makes money primarily through research grants, licensing agreements, and collaboration deals with larger pharmaceutical partners rather than selling approved products. It is based in Lund, Sweden, and operates mainly in Europe, though its clinical trials involve sites across multiple countries. The company's high gross margin reflects the early-stage nature of its revenue, which comes from partnerships rather than commercial sales. The key risk is that Cantargia has no approved drugs yet, meaning its future depends heavily on whether its clinical trials succeed and whether it can secure the funding or partnerships needed to reach the market.